Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 11 , Pages 1110-1119 , November 2009

A Placebo-Controlled, Fixed-Dose Study of Aripiprazole in Children and Adolescents With Irritability Associated With Autistic Disorder

,Accepted 24 June 2009.

References 

  1. APA  . Diagnostic and Statistical Manual of Mental Disorders . 4th ed.. Washington, DC: American Psychiatric Association; 2000;
  2. Chakrabarti S , Fombonne E . Pervasive developmental disorders in preschool children: confirmation of high prevalence . Am J Psychiatry . 2005;162:1133–1141
  3. Fombonne E , Zakarian R , Bennett A , et al.   Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations . Pediatrics . 2006;118:e139–e150
  4. Volkmar F , Cook E , Pomeroy J , et al.   Summary of the practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders . JAm Acad Child Adolesc Psychiatry . 1999;38:1611–1616
  5. Lecavalier L . Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification . J Autism Dev Disord . 2006;36:1101–1114
  6. Lecavalier L , Leone S , Wiltz J . The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders . J Intellect Disabil Res . 2006;50(Pt 3):172–183
  7. Myers SM , Johnson CP . Management of children with autism spectrum disorders . Pediatrics . 2007;120:1162–1182
  8. Research Units on Pediatric Psychopharmacology Autism Network  . Risperidone in children with autism and serious behavioral problems . N Engl J Med . 2002;347:314–321
  9. Shea S , Turgay A , Carroll A , et al.   Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders . Pediatrics . 2004;114:e634–e641
  10. Findling RL , Kauffman RE , Sallee FR , et al.   Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study . J Clin Psychopharmacol . 2008;28:441–446
  11. Findling RL , Robb A , Nyilas M , et al.   A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia . Am J Psychiatry . 2008;165:1432–1441
  12. Biederman J , Mick E , Spencer T , et al.   An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder . CNS Spectr . 2007;12:683–689
  13. Biederman J , McDonnell MA , Wozniak J , et al.   Aripiprazole in the treatment of pediatric bipolar disorder: a systematic chart review . CNS Spectr . 2005;10:141–148
  14. Valicenti-McDermott MR , Demb H . Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities . J Child Adolesc Psychopharmacol . 2006;16:549–560
  15. Stigler KA , Posey DJ , McDougle CJ . Aripiprazole for maladaptive behavior in pervasive developmental disorders . J Child Adolesc Psychopharmacol . 2004;14:455–463
  16. Aman MG , Singh NN . Aberrant Behavior Checklist: Manual . East Aurora, NY: Slosson Educational Publications; 1986;
  17. Lord C , Rutter M , Le Couteur A . Autism Diagnostic Interview–Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders . J Autism Dev Disord . 1994;24:659–685
  18. Scahill L , Riddle MA , McSwiggin-Hardin M , et al.   Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity . J Am Acad Child Adolesc Psychiatry . 1997;36:844–852
  19. Guy W . ECDEU Assessment Manual for Psychopharmacology–Revised . Rockville, MD: U.S. Department of Health Services; 1976;
  20. Varni JW , Seid M , Kurtin PS . PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations . Med Care . 2001;39:800–812
  21. Brannan MA , Heflinger CA , Bickman L . The Caregiver Strain Questionnaire. Measuring the impact on the family of living with a child with serious emotional disturbance . J Emot Behav Disord . 1997;5:212–222
  22. Simpson GM , Angus JW . A rating scale for extrapyramidal side effects . Acta Psychiatr Scand Suppl . 1970;212:11–19
  23. Barnes TR . A rating scale for drug-induced akathisia . Br J Psychiatry . 1989;154:672–676
  24. Guy W , Abnormal Involuntary Movement Scale (AIMS)  . In: ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76–338 . Rockville, MD: National Institute of Mental Health; 1976;p. 534–537
  25. Hochberg Y . A sharper Bonferroni procedure for multiple tests of significance . Biometrika . 1988;75:800–802
  26. Owen R, Findling RL, Carlson G et al. Efficacy and Safety of Aripiprazole in the Treatment of Serious Behavioral Problems Associated with Autistic Disorder: A Double-Blind, Randomized, Placebo-Controlled Trial. 55th Annual Meeting of the American Academy of Child and Adolescent Psychiatry: October 28 to November 2, 2008.

 This study was supported by Bristol-Myers Squibb (Princeton, NJ) and Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan). Editorial support for the preparation of this article was provided by Suzanne Patel and Anna Howarth at Ogilvy Healthworld Medical Education. Bristol-Myers Squibb provided funding for the editorial support. Additional editorial support was provided by Raymond Mankoski of Bristol-Myers Squibb.The authors thank Dan A. Oren, M.D., and Patricia Corey-Lisle, Ph.D. The authors also thank the patients and their caregivers for their participation in this study.

PII: S0890-8567(09)60259-8

doi: 10.1097/CHI.0b013e3181b76658

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 48, Issue 11 , Pages 1110-1119 , November 2009

Article Tools

* Image Usage & Resolution